Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
MOUNTAIN VIEW, Calif., Feb. 29, 2016 -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's fourth quarter 2015 financial results will be released after market close on Monday, March 14, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2016, to discuss these results and to answer questions.
To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 58052541. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II studies for the treatment of atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. CCX140, a distinct CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in albuminuria in patients with diabetic nephropathy. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development, vercirnon (also known as Traficet-EN or CCX282) a specific CCR9 inhibitor for the treatment of inflammatory bowel disease, and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
CCXI-G
Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer [email protected] Media: Denise Powell 510.703.9491 [email protected] Investors: Steve Klass Burns McClellan 212.213.0006 [email protected]
